Mentari Therapeutics Acquired by InMed Pharmaceuticals | Healthcare M&A Deal

InMed Pharmaceuticals has acquired Mentari Therapeutics, a pharmacy business in New York, for $421 million. Mentari Therapeutics is developing antibody-based migraine prevention therapies targeting PACAP to address headaches not controlled by existing drugs, supporting a focused healthcare M&A strategy in NY acquisitions. InMed Pharmaceuticals acquisitions aim to build a combined company operating under the Mentari name, with clinical milestones expected through 2028. The merger acquisition is announced, backed by a strategic acquisition profile and a concurrent private placement expected to provide about $290 million in gross proceeds, with board approvals already secured and a closing targeted for the back half of the year.